Virion Therapeutics, LLC☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Virion Therapeutics, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Virion Therapeutics, LLC is one of 4293 Biotechnology companies tracked from NEWARK. By capital raised it ranks mid-pack (ahead of 58% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

This issuer has a dense recurring filing history, so the chart groups filings by year. Solid bars are annual reported capital reported; hatched bars show the latest modeled value est. observed in that year. Use the toggles to overlay data labels and the niche-peer / market average value lines.

This looks like a recurring offering series, so a VC stage ladder would be misleading. Showing the filed offering sequence instead.

Showing first 24 of 25 filings to keep the sequence readable.

This issuer files recurring offerings, so the model treats stage labels as a loose sizing heuristic, not a clean VC ladder. The estimate anchors on reported filing amounts and dates, then applies benchmark dilution, survival, and markup assumptions. Directional, not a quoted figure.

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 58% of sector peers (real $). Modeled value above 72% of peers (estimate).

This issuer files too frequently for VC stage labels to be meaningful, so rows are shown as initial/follow-on offerings est. instead of Pre-Seed/Seed/Series buckets.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Initial offering$2.1M2017-06-28
   • First recorded raise — entered as Initial offering.
   • 35 investors on this round.
2. Follow-on offering$5.2M2018-06-28
   • Raised 12 mo later, in step with the ~14 mo sector norm.
   • Round 2.4× larger than the prior — scaling up.
   • 78 investors on this round.
3. Follow-on offering$2.1M2018-06-28
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 2.4× smaller than the prior — bridge or down round.
   • 35 investors on this round.
4. Follow-on offering$5.2M2018-06-28
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 2.5× larger than the prior — scaling up.
   • 80 investors on this round.
5. Follow-on offering$4.9M2018-06-28
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round roughly the size of the prior one.
   • 78 investors on this round.
6. Follow-on offering$4.1M2018-06-28
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round roughly the size of the prior one.
   • 70 investors on this round.
7. Follow-on offering$3.7M2018-06-28
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round roughly the size of the prior one.
   • 65 investors on this round.
8. Follow-on offering$3.1M2019-10-28
   • Raised 16 mo later, in step with the ~14 mo sector norm.
   • Round roughly the size of the prior one.
   • 34 investors on this round.
9. Follow-on offering$1.1M2019-10-28
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 2.8× smaller than the prior — bridge or down round.
   • 20 investors on this round.
10. Follow-on offering$2.8M2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.6× larger than the prior — scaling up.
    • 32 investors on this round.
11. Follow-on offering$695K2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.1× smaller than the prior — bridge or down round.
    • 9 investors on this round.
12. Follow-on offering$545K2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 7 investors on this round.
13. Follow-on offering$495K2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 7 investors on this round.
14. Follow-on offering$250K2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 4 investors on this round.
15. Follow-on offering$1.1M2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.5× larger than the prior — scaling up.
    • 22 investors on this round.
16. Follow-on offering$1.9M2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× larger than the prior — scaling up.
    • 31 investors on this round.
17. Follow-on offering$3.0M2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× larger than the prior — scaling up.
    • 33 investors on this round.
18. Follow-on offering$1.2M2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.4× smaller than the prior — bridge or down round.
    • 25 investors on this round.
19. Follow-on offering$3.4M2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.7× larger than the prior — scaling up.
    • 37 investors on this round.
20. Follow-on offering$960K2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.5× smaller than the prior — bridge or down round.
    • 16 investors on this round.
21. Follow-on offering$595K2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.6× smaller than the prior — bridge or down round.
    • 8 investors on this round.
22. Follow-on offering$695K2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 11 investors on this round.
23. Follow-on offering$3.9M2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 5.6× larger than the prior — scaling up.
    • 40 investors on this round.
24. Follow-on offering$5.7M2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× larger than the prior — scaling up.
    • 49 investors on this round.
25. Follow-on offering$1.3M2019-10-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.4× smaller than the prior — bridge or down round.
    • 23 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

Virion Therapeutics, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Virion Therapeutics, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Virion Therapeutics, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.